Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc (KPTI) is a leader in developing novel cancer therapies through its pioneering research in nuclear export inhibition. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time announcements about XPOVIO (selinexor) developments, pipeline progress across multiple oncology indications, and global commercialization efforts. Our curated collection includes press releases on FDA approvals, clinical trial results, partnership agreements, and financial disclosures.
Key updates cover therapeutic innovations in multiple myeloma, myelofibrosis, and other high-need cancers. Stay informed about Karyopharm's scientific leadership through objective reporting of peer-reviewed data and market expansion activities. Bookmark this page for direct access to primary source materials that drive informed analysis.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced the granting of 1,850 restricted stock units (RSUs) to two newly-hired employees as of March 31, 2025.
The RSU awards, granted under the Company's 2022 Inducement Stock Incentive Plan, will vest over three years, with 33 1/3% vesting on each anniversary of the Grant Date. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements. Additionally, the RSUs include an acceleration clause allowing immediate full vesting if employment is terminated for 'good reason' or without 'cause' within one year of a change in control event.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced the granting of 3,316 restricted stock units (RSUs) to five newly-hired employees as of February 28, 2025.
The RSU awards, granted under the Company's 2022 Inducement Stock Incentive Plan, will vest over three years, with 33 1/3% vesting on each anniversary of the Grant Date. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) as employment inducements.
The RSUs include an acceleration clause that allows for immediate full vesting if the employee's employment is terminated for 'good reason' or without 'cause' within one year of a change in control event.
Karyopharm Therapeutics (KPTI) has announced a 1-for-15 reverse stock split effective February 25, 2025, at 5:00 p.m. Eastern Time. The split aims to increase the per-share market price to regain compliance with Nasdaq's minimum bid price requirement.
The stock will begin trading on a split-adjusted basis on February 26, 2025. The reverse split will reduce outstanding shares from approximately 126.2 million to 8.4 million, and authorized shares from 800 million to 53.3 million. Proportionate adjustments will be made to equity incentive plans, outstanding equity awards, warrants, and convertible notes.
No fractional shares will be issued; stockholders will receive cash payments instead. Computershare Trust Company is acting as the exchange agent, and stockholders holding shares electronically need not take action to receive post-split shares.
Karyopharm Therapeutics reported financial results for Q4 and full year 2024, achieving total revenue of $145.2 million and U.S. XPOVIO net product revenue of $112.8 million for the full year. The company provided 2025 guidance with total revenue expected between $140-155 million.
Key updates include modifications to the Phase 3 XPORT-EC-042 trial in endometrial cancer, with enrollment now focusing on patients with pMMR tumors or dMMR tumors ineligible for checkpoint inhibitors. The sample size has been increased to 276 patients, with top-line data expected in mid-2026.
The Phase 3 SENTRY trial in myelofibrosis is on track for enrollment completion in 1H 2025, with top-line data expected in 2H 2025. The company's cash position was $109.1 million as of December 31, 2024, expected to fund operations into Q1 2026.
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has scheduled its fourth quarter and full year 2024 financial results announcement for Wednesday, February 19, 2025. The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day.
Investors can access the conference call via phone at (800) 836-8184 (local) or (646) 357-8785 (international). The webcast and accompanying slides will be available in the Investor section of Karyopharm's website under 'Events & Presentations', with an archived version accessible approximately two hours after the event.
Karyopharm Therapeutics (Nasdaq: KPTI) has announced the granting of 28,000 restricted stock units (RSUs) to three newly-hired employees as of January 31, 2025. These RSU awards were granted under the Company's 2022 Inducement Stock Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over three years, with 33 1/3% vesting on each anniversary of the grant date, contingent upon continued employment. In case of a change in control event, the RSUs will fully vest if the employee's employment is terminated for good reason or without cause within one year of such event.
Karyopharm Therapeutics (KPTI) announced preliminary unaudited 2024 results and 2025 objectives. The company expects total revenue of approximately $145 million and U.S. XPOVIO net product revenue of $113 million for full year 2024.
Key highlights include the Phase 3 SENTRY trial evaluating selinexor in myelofibrosis, with top-line results expected in H2 2025. The company updated the trial's co-primary endpoint to absolute mean change in total symptom score (Abs-TSS) and increased the sample size to 350 patients.
XPOVIO showed consistent demand in 2024 versus 2023, with growth in H2 2024 in both community and academic settings. The drug is now approved in over 45 countries. Cash position stands at approximately $109 million as of December 31, 2024, expected to fund operations into Q1 2026.
Karyopharm Therapeutics (NASDAQ: KPTI) has announced equity grants to four newly-hired employees as of December 31, 2024. The grants include 101,250 stock options with an exercise price of $0.6763 per share and 108,540 restricted stock units (RSUs).
The stock options vest over four years, with 25% vesting after one year and 1/48th monthly thereafter. The RSUs vest over three years, with 33 1/3% vesting annually. Both grants require continued employment with Karyopharm. In case of a change in control event followed by termination for good reason or without cause within one year, all grants will immediately vest in full.
Karyopharm Therapeutics (Nasdaq: KPTI) has appointed Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. Macomber brings over 20 years of experience in life science companies' financial management, most recently serving as CFO at Legend Biotech
As part of her appointment, Macomber will receive inducement awards including a non-statutory stock option to purchase 650,000 shares and 160,000 restricted stock units (RSUs). The stock options will vest over four years, with 25% vesting after the first year and 1/48th monthly thereafter. The RSUs will vest over three years, with 33 1/3% vesting annually. Both awards include immediate vesting provisions in case of a change in control event followed by qualifying termination.
Karyopharm Therapeutics (Nasdaq: KPTI) has appointed Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. Strong joins from Argot Partners, where he served as Managing Director advising biopharmaceutical companies. His previous experience includes roles as investor relations lead at Tenet Healthcare, CFO of Tenet's Massachusetts Market, and equity research positions at Lehman Brothers and Barclays.
The company emphasizes Strong's experience will be valuable as they approach important milestones in 2025, particularly in advancing their late-stage pipeline and building on their multiple myeloma foundation. Strong holds an MBA from Harvard Business School and a B.S. in Finance from Rutgers University.
